This invention provides a method for introducing substances into cells comprising contacting a composition comprising orally administered beta-glucan with said cells. This invention also provides a method for introducing substances into a subject comprising administering to the subject an effective
This invention provides a method for introducing substances into cells comprising contacting a composition comprising orally administered beta-glucan with said cells. This invention also provides a method for introducing substances into a subject comprising administering to the subject an effective amount of the above compositions. The substance, which could be delivered orally includes but is not limited to peptides, proteins, RNAs, DNAs, chemotherapeutic agents, biologically active agents, plasmids, and other small molecules and compounds. Finally, this invention provides a composition comprising orally administered beta-glucan capable of enhancing efficacy of IgM and different uses of the said composition.
대표청구항▼
What is claimed is: 1. A composition comprising: (a) a composition comprising an antibody that binds to a cancer cell, and at least one pharmaceutically acceptable carrier, wherein the cancer is selected from the group consisting of neuroblastoma, melanoma, non-Hodgkin's lymphoma, breast cancer, Ep
What is claimed is: 1. A composition comprising: (a) a composition comprising an antibody that binds to a cancer cell, and at least one pharmaceutically acceptable carrier, wherein the cancer is selected from the group consisting of neuroblastoma, melanoma, non-Hodgkin's lymphoma, breast cancer, Epstein-Barr related lymphoma, Hodgkin's lymphoma, and epidermoid carcinoma; and (b) an orally administered composition comprising at least one pharmaceutically acceptable carrier and a soluble β-glucan in an amount effective to enhance the antitumor effect of said antibody, wherein the β-glucan comprises a β-1,3 backbone and at least one β-1,3 side chain of two or more glucose units linked to the backbone by a β-1,6 glycosidic bonds. 2. The composition of claim 1, wherein the β-glucan is isolated from yeast. 3. The composition of claim 1, wherein the β-glucan is isolated from Saccharomyces Cerevisiae. 4. The composition of claim 1, wherein the β-glucan has a molecular weight from about 10 kDa to about 350 kDa. 5. The composition of claim 1, wherein the antibody is a monoclonal antibody or a complement-activating antibody. 6. The composition of claim 1, wherein the antibody binds to a cancer cell expressing an antigen selected from the group consisting of CD20, HER2, EGFR, GD2, and GD3. 7. The composition of claim 1, wherein the antibody is further capable of activating an antibody dependent cell-mediated cytotoxicity response. 8. A composition comprising: (a) a composition comprising an antibody that binds to a cancer cell, and at least one pharmaceutically acceptable carrier, wherein the antibody binds to a cancer cell expressing an antigen selected from the group consisting of CD20, HER2, EGFR, GD2, and GD3; and (b) an orally administered composition comprising at least one pharmaceutically acceptable carrier and a soluble β-glucan in an amount effective to enhance the antitumor effect of said antibody, wherein the β-glucan comprises a β-1,3 backbone and at least one β1,3 side chain of two or more glucose units linked to the backbone by a β-1,6 glycosidic bond. 9. The composition of claim 8, wherein the β-glucan is isolated from yeast. 10. The composition of claim 8, wherein the β-glucan is isolated from Saccharomyces Cerevisiae. 11. The composition of claim 8, wherein the β-glucan has a molecular weight from about 10 kDa to about 350 kDa. 12. The composition of claim 8, wherein the antibody is a monoclonal antibody or a complement-activating antibody. 13. The composition of claim 8, wherein the cancer cell is selected from the group consisting of neuroblastoma, melanoma, non-Hodgkin's lymphoma, breast cancer, Epstein-Barr related lymphoma, Hodgkin's lymphoma, and epidermoid carcinoma. 14. The composition of claim 8, wherein the antibody is further capable of activating an antibody dependent cell-mediated cytotoxicity response.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (47)
Kozbor,Danuta; Kaneko,Yutaro, β-glucans encapsulated in liposomes.
Nikl Libor H. (Port Coquitlam CAX) Allbright Lawrence J. (Burnaby CAX), Composition and method to enhance the efficacy of a fish vaccine and to stimulate the immune system of fish.
Jamas Spiros ; Easson ; Jr. D. Davidson ; Ostroff Gary R., Enhancement of non-specific immune defenses by administration of underivatized, aqueous soluble glucans.
Bondeson Anders (Gothenburg SEX) Isaak Bernhard (Lausanne CHX) Perrenoud Andre (Nyon CHX) Tran Minh Q. (Lausanne CHX), High-performance gyrotron for production of electromagnetic millimeter or submillimeter waves.
Cheever Martin A. ; Disis Mary L., Immune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is a.
Cheever, Martin A.; Disis, Mary L., Immune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is associated.
Lane H. Clifford (Bethesda MD) Kovacs Joseph A. (Potomac MD) Fauci Anthony S. (Washington DC), Immunologic enhancement with intermittent interleukin-2 therapy.
Jamas Spiros (Boston MA) Easson ; Jr. D. Davidson (Shrewsbury MA) Ostroff Gary R. (Worcester MA), Method for immune system activation by administration of a b
상세보기
Jamas Spiros (Boston MA) Easson ; Jr. D. Davidson (Shrewsbury MA) Ostroff Gary R. (Worcester MA), Method for producing neutral glucans for pharmaceutical applications.
Williams David L. (River Ridge LA) Browder I. William (New Orleans LA) DiLuzio ; deceased Nicholas R. (late of Gretna LA by Nicholas M. DiLuzio ; legal representative), Methods and compositions for prophylactic and therapeutic treatment of infections.
Williams David L. (River Ridge LA) Browder I. William (New Orleans LA) Diluzio ; deceased Nicholas R. (late of Gretna LA by Nicholas M. Diluzio ; legal representative), Methods and compositions for prophylactic and therapeutic treatment of infections.
Robbins Ernest A. (High Ridge MO) Seeley Robert D. (Crestwood MO), Process for the prevention and reduction of elevated blood cholesterol and triglycerides levels.
Williams David L. (River Ridge LA) Browder I. William (New Orleans LA) DiLuzio ; deceased Nicholas R. (late of New Orleans LA by Nicholas M. DiLuzio ; legal representative), Soluble phosphorylated glucan: methods and compositions for treatment of neoplastic diseases.
Donzis Byron A. (#18 W. Rivercrest Houston TX 77042), Substantially purified beta (1,3) finely ground yeast cell wall glucan composition with dermatological and nutritional u.
Donzis Byron A. (#18 W. Rivercrest Houston TX 77042), Substantially purified beta (1,3) finely ground yeast cell wall glucan composition with dermatological and nutritional u.
Jamas Spiros (Boston MA) Easson ; Jr. D. Davidson (Shrewsbury MA) Ostroff Gary R. (Worcester MA), Use of aqueous soluble glucan preparations to stimulate platelet production.
Jamas Spiros ; Easson ; Jr. D. Davidson ; Ostroff Gary R., Uses for underivatized, aqueous soluble .beta.(1-3) glucan and compositions comprising same.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.